CAP

Clinical Genomics Announces New Publication from Flinders Medical Centre, Highlighting the Use of COLVERA® as a Quantitative ctDNA Biomarker for Response to Colorectal Cancer Therapy

Retrieved on: 
Friday, February 18, 2022
Methylation, Colorectal cancer, Patient, Observational study, CEO, Risk, Man, Clinical, Recurrence, HIV disease progression rates, Flinders University, Gastroenterology, Solution, Risk assessment, BCAT1, Large intestine, MD, Woman, Completeness, Disease, Biomarker, Physician, CAP, IKZF1, Diagnosis, Genomics, DNA, Neoplasm, Molecular oncology, Level, CRC, GLOBE, Gene, Laboratory developed test, Medical imaging, Cancer

BRIDGEWATER, N.J., Feb. 18, 2022 (GLOBE NEWSWIRE) -- Clinical Genomics, a provider of cancer diagnostic solutions, including liquid biopsy tests for molecular residual disease (“MRD”) and recurrence monitoring of colorectal cancer (“CRC”), today announced a new publication from researchers at the prestigious Flinders Centre for Innovation in Cancer, Flinders Medical Center in Adelaide, S. Australia on COLVERA®. COLVERA, a circulating tumor DNA (“ctDNA”) test that looks for methylation in two genes (BCAT1 and IKZF1), showed that ctDNA is an effective biomarker for risk assessment for residual CRC post-treatment.

Key Points: 
  • This observational study provides further data to support the use of COLVERA to monitor patients throughout their CRC journey.
  • COLVERA methylation Biomarkers detect presence of disease in CRC patients regardless of their tumor stage, heterogeneity, or individual mutational profiles.
  • We are highly encouraged that the findings support the use of COLVERA as a quantitive ctDNA biomarker for response to CRC therapy.
  • Clinical Genomics products span the full spectrum of colorectal cancer testing from screening to post-treatment monitoring.

New CAP Guideline Improves Testing, Care, for Patients with Diffuse Gliomas

Retrieved on: 
Thursday, February 17, 2022
Science, Other Science, Radiology, Managed Care, Oncology, Health, Genetics, Other Health, Pathology, Archives of Pathology & Laboratory Medicine, Patient, National academy, Prognosis, The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, 2021 Essex County Council election, Doctor of Philosophy, Association for Molecular Pathology v. Myriad Genetics, Inc., World, Diagnosis, Society, College, Oligodendroglioma, IDH, Adult, Development, Leadership, GRADE, Glioma, Neoplasm, WHO, Guideline, Oligoastrocytoma, Astrocytoma, READ, Mutation, National Academy of Medicine, Marie Cassidy, Classification, Disease, CAP, Medical laboratory, American Association, Association, World Health Organization, American Association of Neuropathologists, Medical imaging, Dietary supplement, MD

Diffuse gliomas affect approximately 15,000 people in the US each year and present with widely variable clinical courses and treatment approaches.

Key Points: 
  • Diffuse gliomas affect approximately 15,000 people in the US each year and present with widely variable clinical courses and treatment approaches.
  • Traditionally, diffuse gliomas have been classified by their microscopic properties as astrocytomas, oligodendrogliomas, or oligoastrocytomas ranging from World Health Organization (WHO) grades 2 to 4.
  • With the new CAP guideline, clinical teams now have evidence-based guidance for diffuse glioma molecular testing more broadly, which can help improve the diagnosis, prognosis, and therapeutic care for patients.
  • Offers guidance specific to biomarker testing in pediatric patients with diffuse gliomas.

AXIM Biotech Announces New Milestones in Preparation of Dry Eye Disease Diagnostics Launch

Retrieved on: 
Tuesday, February 15, 2022
IUL, Duane syndrome, SAN, Drug Quality and Security Act, Private Securities Litigation Reform Act, College, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Technology, COLA, LED, Automation, COVID-19, Lactoferrin, LLC, Health, Company, SEC, Compliance, Securities Act of 1933, DED, MAB, MLO, Research, Diagnosis, Industry, Incidence, OTCQB, Publication, Marketing, Microbiology, Severe acute respiratory syndrome coronavirus 2, Ophthalmology, GLOBE, Patient, Generalist, Food, CEO, Forward-looking statement, IP, Annual report, Securities Exchange Act of 1934, Administrator, Commission, FDA, CLIA, Laboratory, CAP, Pharmaceutical industry, Book, Medical device, Biotechnology

SAN DIEGO, Feb. 15, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (AXIM Biotech, AXIM or the Company), an international healthcare solutions company targeting dry eye disease (DED), today announced two key milestones in preparation of the launch of its DED diagnostics testing initiative.

Key Points: 
  • SAN DIEGO, Feb. 15, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (AXIM Biotech, AXIM or the Company), an international healthcare solutions company targeting dry eye disease (DED), today announced two key milestones in preparation of the launch of its DED diagnostics testing initiative.
  • iPeak is equipped with Flash Eye technology based on the principles of machine vision illumination.
  • AXIM evaluated the iPeak readers in the lab against six other comparable products before deciding on IULs state-of-the-art products.
  • Founded in 2014, AXIM Biotechnologies, Inc. (AXIM) is a vertically integrated research and development company focused on improving the landscape for diagnosis of ophthalmological conditions such as Dry Eye Disease (DED) through rapid diagnostic tests.

(ISC)² Expands Events Portfolio with the Launch of SECURE Summits

Retrieved on: 
Wednesday, February 16, 2022
Zero, CBK, Work, Certified Information Systems Security Professional, CEO, Certification, Center, Facebook, National Special Security Event, Association, LinkedIn, Twitter, CPE, Software, CAP, ISC, SSCP, CCSP, Education, Industry, CISSP, 2012 Nuclear Security Summit, Medical device, Risk management

One-day, in-person events will take place this year in Washington, D.C. , London and Singapore .

Key Points: 
  • One-day, in-person events will take place this year in Washington, D.C. , London and Singapore .
  • "With that feedback in mind, we're excited to launch the SECURE Summits, providing the community with exceptional content and insights specific to where they live and work and opportunities to reconnect and learn from one another."
  • Engagements and connections made at events like SECURE Summits play a pertinent role in influencing smarter cyber policies and standards around the world, developing and expanding the cybersecurity community, and inspiring a safe and secure cyber world.
  • The in-person 2022 SECURE Events will take place on the following dates:
    The virtual 2022 SECURE Events will take place on the following dates:
    Members can earn CPE credits for their attendance.

GSX Joins (ISC)² Official Training Partner Program

Retrieved on: 
Tuesday, February 15, 2022
CBK, Certified Information Systems Security Professional, Professional, OTP, CEO, Official, Certification, Education, GSX, SME, Center, Facebook, Solution, Asia-Pacific, Outline, Organization, Association, LinkedIn, Twitter, Software, CAP, ISC, SSCP, CCSP, Government, Industry, Program, CISSP, Medical device, Risk management, Medicine

HONG KONG, Feb. 15, 2022 /PRNewswire/ -- (ISC) the world's largest nonprofit association of certified cybersecurity professionals today announced that Global Security Experts, Inc. (GSX) has joined its Official Training Partner ( OTP ) program to deliver cybersecurity education and professional development for practitioners in Japan and Bangladesh.

Key Points: 
  • HONG KONG, Feb. 15, 2022 /PRNewswire/ -- (ISC) the world's largest nonprofit association of certified cybersecurity professionals today announced that Global Security Experts, Inc. (GSX) has joined its Official Training Partner ( OTP ) program to deliver cybersecurity education and professional development for practitioners in Japan and Bangladesh.
  • GSX is committed to bringing the highest possible training and education standards to the region," said Clayton Jones, managing director, Asia-Pacific, (ISC).
  • "Together with the Official CISSP CBK Training, GSX will strive to improve the self-defense capabilities of companies throughout Japan."
  • To find out more about (ISC) Official Training Partners and to find training courses offered by GSX, please visit: https://www.isc2.org/Training/providers
    (ISC) is an international nonprofit membership association focused on inspiring a safe and secure cyber world.

Inivata and Collaborators Publish Positive Results from Prospective Clinical Study of RaDaR™ in Head and Neck Squamous Cell Carcinoma

Retrieved on: 
Friday, February 11, 2022
NASDAQ, Patient, University of Cambridge, Liquid, Cancer research, LMU Klinikum, Risk, Faculty, Department, Recurrence, Doctor of Philosophy, Liquid biopsy, MRD, Radar, LMU, VAF, Breast, Triangle Park (Quezon City), Technology, US, Research Triangle Park, Institute, Medical school, Minimal, Biotechnology, CLIA, D, Laboratory, Disease, CAP, NSCLC, Head, Research, DNA, Neoplasm, University, NeoGenomics, Medical imaging, Pathology, Medicine, HNSCC

Research Triangle Park, NC, USA and Cambridge, UK, 11 February 2022 -- Inivata, a leader in liquid biopsy, today announced clinical validation data for its RaDaRTM liquid biopsy test in head and neck squamous cell carcinoma (HNSCC). The data from the Liquid BIOpsy for MiNimal RESidual DiSease Detection in Head and Neck Squamous Cell Carcinoma (LIONESS) study have been published in the British Journal of Cancer and can be viewed here. The study was in collaboration with the Department of Otorhinolaryngology, Head and Neck Surgery (ORL-HNS), LMU Klinikum, and Institute of Pathology, Faculty of Medicine, LMU Munich.​

Key Points: 
  • Research Triangle Park, NC, USA and Cambridge, UK, 11 February 2022 -- Inivata, a leader in liquid biopsy, today announced clinical validation data for its RaDaRTM liquid biopsy test in head and neck squamous cell carcinoma (HNSCC).
  • The data from the Liquid BIOpsy for MiNimal RESidual DiSease Detection in Head and Neck Squamous Cell Carcinoma (LIONESS) study have been published in the British Journal of Cancer and can be viewed here .
  • The study was in collaboration with the Department of Otorhinolaryngology, Head and Neck Surgery (ORL-HNS),LMU Klinikum, and Institute of Pathology, Faculty of Medicine, LMU Munich.
  • In the remaining 12 patients there was no recurrence detected, indicating a 100% clinical specificity of the RaDaR assay and confirming post-operative tumor clearance.

(ISC)² to Pilot Online Proctored Exams for CISSP in U.S., U.K. and Singapore

Retrieved on: 
Monday, February 14, 2022
Online, CBK, Certified Information Systems Security Professional, CAT, Time, Certification, Pearson VUE, Center, Facebook, Association, LinkedIn, Twitter, Software, CAP, ISC, SSCP, CCSP, Education, Industry, Computerized adaptive testing, CISSP, Tutoring, Medicine

Built on learnings from the association's first online proctored pilot test in 2021 , this pilot program is designed to further assess the viability, and help determine the potential future availability, of online proctoring for (ISC) certification examinations.

Key Points: 
  • Built on learnings from the association's first online proctored pilot test in 2021 , this pilot program is designed to further assess the viability, and help determine the potential future availability, of online proctoring for (ISC) certification examinations.
  • With exam security the primary objective, (ISC) has established new identity validation and security processes for this second pilot of online proctored exams.
  • Online CISSP examinations will be administered February 28 March 7, 2022 for candidates physically located in the U.S., U.K. and Singapore.
  • 2022 (ISC) Inc., (ISC), CISSP, SSCP, CCSP, CAP, CSSLP, HCISPP, CISSP-ISSAP, CISSP-ISSEP, CISSP-ISSMP and CBK are registered marks of (ISC), Inc.

FDA Grants Breakthrough Designation for Datar Cancer Genetics Early-Stage Prostate Cancer Detection Blood Test

Retrieved on: 
Monday, February 14, 2022
Breakthrough, Chinese, Patient, Biopsy, Program, Food, Cancer, Game Changer, Device, Company, Certification, Prostate cancer, Test, Death, ISO, US, PSA, FDA, CLIA, Prostate, US Foods, Blood, CAP, Serum, CTC, Genetics, Diagnosis, CE, NABL, Medical imaging, Guildford

LONDON, Feb. 14, 2022 /PRNewswire/ -- Datar Cancer Genetics today announced that the US Food and Drug Administration (FDA) has granted 'Breakthrough Device Designation' for its blood test to detect early-stage prostate cancer. This is the second test from the Company that has received the Breakthrough Device Designation from the US FDA. Last year, the Company's early-stage breast cancer detection test became the first such test to receive the Breakthrough Device Designation.

Key Points: 
  • LONDON, Feb. 14, 2022 /PRNewswire/ -- Datar Cancer Genetics today announced that the US Food and Drug Administration (FDA) has granted 'Breakthrough Device Designation' for its blood test to detect early-stage prostate cancer.
  • This is the second test from the Company that has received the Breakthrough Device Designation from the US FDA.
  • Last year, the Company's early-stage breast cancer detection test became the first such test to receive the Breakthrough Device Designation.
  • In Europe, prostate cancer is the second most common type of cancer among males with detection of an estimated 500,000 cases and 100,000 deaths in 2022.

FDA Grants Breakthrough Designation for Datar Cancer Genetics Early-Stage Prostate Cancer Detection Blood Test

Retrieved on: 
Monday, February 14, 2022
Breakthrough, Chinese, Patient, Biopsy, Program, Food, Cancer, Man, Company, Certification, Device, Prostate cancer, Death, Trinetra, ISO, US, PSA, FDA, CLIA, Prostate, US Foods, Blood, CAP, Serum, CTC, Genetics, Diagnosis, CE, NABL, Medical imaging

BOSTON, Feb. 14, 2022 /PRNewswire/ -- Datar Cancer Genetics Inc today announced that the US Food and Drug Administration (FDA) has granted 'Breakthrough Device Designation' for its 'TriNetra-Prostate™' blood test to detect early-stage prostate cancer. This is the second test from the Company that has received the Breakthrough Device Designation from the US FDA. Last year, the Company's early-stage breast cancer detection test became the first such test to receive the Breakthrough Device Designation.

Key Points: 
  • BOSTON, Feb. 14, 2022 /PRNewswire/ -- Datar Cancer Genetics Inc today announced that the US Food and Drug Administration (FDA) has granted 'Breakthrough Device Designation' for its 'TriNetra-Prostate' blood test to detect early-stage prostate cancer.
  • This is the second test from the Company that has received the Breakthrough Device Designation from the US FDA.
  • Last year, the Company's early-stage breast cancer detection test became the first such test to receive the Breakthrough Device Designation.
  • In the United States, prostate cancer is the third most common type of cancer; each year, more than 200,000 men are detected with prostate cancer and is associated with more than 32,000 deaths.

COVID-19-Induced Stillbirths Caused by Placental Destruction and Failure

Retrieved on: 
Thursday, February 10, 2022
Health, Consumer, Infectious Diseases, Women, Other Health, Research, Science, Omicron, Woman, Prevention, Viremia, Fetus, Medical laboratory, Fibrin, Death, Marie Cassidy, Stillbirth, COVID-19, Mother, Abnormality, Parasitism, Research, Cell, Placental insufficiency, Vaccination, CAP, Infection, Annual report, Risk, Pregnancy, Patient, Oxygen, Archive, Severe acute respiratory syndrome coronavirus 2, Necrosis, Pathology, Autopsy, Archives of Pathology & Laboratory Medicine, Coagulation, College, Placenta, Pharmaceutical industry, Vaccine, Delta, MD

In November, the U.S. Centers for Disease Control and Prevention reported that pregnant women with COVID-19 have increased risk for stillbirths.

Key Points: 
  • In November, the U.S. Centers for Disease Control and Prevention reported that pregnant women with COVID-19 have increased risk for stillbirths.
  • Our study identified placental insufficiency as the root cause for stillbirths in women with COVID-19 during pregnancy.
  • The viral-induced lesions in the placenta obstructed maternal and fetal blood flow and oxygen exchange and caused irreparable damage and necrosis of placental tissues.
  • Worldwide, it is estimated there are up to six million stillbirths a year, and most result from placental failure.